US approves Gilead's twice-yearly injection to prevent HIV / Photo: JUSTIN SULLIVAN - GETTY IMAGES NORTH AMERICA/AFP
-
BYD Drops Rotating Screens in New Models Due to Tech Limits
-
Samsung Leads Global DRAM Market as SK Hynix Gains Share
-
South Korea Proposes Fourth Delay of Cryptocurrency Gains Tax to 2029
-
Kakao Details Spinoff Plan to Monetize AI Through KakaoTalk
-
ASIC Fines Mona Museum Owner's Company for Late Financial Report
-
Business Leaders Condemn Productivity Commission Inquiry for Excluding Tax and Labor Issues
-
Business Leaders Criticize Productivity Commission Inquiry Scope
-
Sheikh Hasina Vows Return to Bangladesh Despite Death Sentence
-
SCANDIC FINANCE ने एलेक्स बोडी को समूह का उपाध्यक्ष नियुक्त किया
-
SCANDIC FINANCE แต่งตั้งอเล็กซ์ โบดี เป็นรองประธานกลุ่มบริษัท
-
SCANDIC FINANCE Grubu, Alex Bodi’yi başkan yardımcılığına atadı
-
Alex Bodi wiceprezesem grupy SCANDIC FINANCE
-
Алекс Боди е назначен за вицепрезидент на групата SCANDIC FINANCE
-
Alex Bodi a SCANDIC FINANCE vállalatcsoport új alelnöke
-
Ο Άλεξ Μπόντι νέος αντιπρόεδρος του ομίλου SCANDIC FINANCE
-
Alex Bodi byl jmenován viceprezidentem skupiny SCANDIC FINANCE
-
Alex Bodi utsedd till vicepresident för SCANDIC FINANCE-koncernen
-
تعيين أليكس بودي نائبًا لرئيس مجموعة SCANDIC FINANCE
-
SCANDIC FINANCEグループ、アレックス・ボディ氏を副社長に任命
-
SCANDIC FINANCE 그룹, 알렉스 보디 부사장 선임
US approves Gilead's twice-yearly injection to prevent HIV
The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV, a move the company hailed as a major breakthrough in the fight against the sexually transmitted virus.
Drugs to prevent HIV transmission, known as pre-exposure prophylaxis or PrEP, have existed for more than a decade. But because they typically require taking a daily pill, they have struggled to make a significant dent in global infections.
"This is a historic day in the decades-long fight against HIV," said Daniel O'Day, Gilead's chairman and chief executive officer, in a statement.
Lenacapavir, marketed under the brand name Yeztugo, has been shown in clinical trials to reduce the risk of HIV transmission by more than 99.9 percent in adults and adolescents -- making it functionally akin to a powerful vaccine.
But optimism may be tempered by the drug's expected eye-watering price tag.
While the company has not disclosed specifics, analysts estimate the US launch price could be as high as $25,000 per year.
Activists are calling for the price to be slashed to $25 per person annually to help end the HIV pandemic.
The approval also comes as President Donald Trump's administration has slashed funding for HIV treatment and prevention programs both overseas and within the United States.
E.Ramalho--PC
